Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic
Dissociative Disorders, Schizophrenia
About this trial
This is an interventional other trial for Dissociative Disorders
Eligibility Criteria
Inclusion Criteria:
- Male or female patients
- Aged from 6 to 18 years
- In whom antipsychotic treatment is indicated
- Who have never been treated with antipsychotic medication (other than metoclopramide (Primperan®) for pediatric indications) or with a history of antipsychotic over a maximum period of three consecutive months and discontinued for at least 6 months. .
The non-inclusion criteria:
- Any
The exclusion criteria:
- Refusal or withdrawal of consent by the patient or his/her parents.
Sites / Locations
- CH de Cannes
- Service de psychiatrie de l'enfant et de l'adolescent
- CH D'antibes
- CH Henri laborit
- Fondation Vallée
- Ch le Vinatier
- CHRU de Lille
- Centre Hospitalier Spécialisé Esquirol
- CH St Jean de Dieu
- HCL
- CHU de Nancy
- CHU de Nantes
- AP-HP
- CHU de Toulouse
Arms of the Study
Arm 1
Other
rispéridone, aripiprazole, olanzapine...
Study: We propose a prospective, interventional multicenter study. Method: Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug. The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug.